Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab

The checkpoint inhibitor nivolumab is active in metastatic melanoma patients who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab refractory patients with unresectable stage III or IV melanoma, including those who experienced grade 3-4 drug relat...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Immunol Res
Glavni autori: Weber, Jeffrey, Gibney, Geoffrey, Kudchadkar, Ragini, Yu, Bin, Cheng, PingYan, Martinez, Alberto J., Kroeger, Jodie, Richards, Allison, McCormick, Lori, Moberg, Valerie, Cronin, Heather, Zhao, Xiuhua, Schell, Michael, Chen, Yian Ann
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4818672/
https://ncbi.nlm.nih.gov/pubmed/26873574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-15-0193
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items